SBIR Phase I: Nano Technology Buccal Drug Delivery Platform

这个小型企业创新研究(SBIR)第一阶段项目寻求开发一种新型的药物输送平台，该平台使用一种有效的纳米胶囊方法，能够通过口腔粘膜局部和系统地输送各种药物。载药纳米粒(NPs)受到保护并安置在生物基质海绵中，海绵还可以含有渗透促进剂和特定的靶向基序。这些组件的结合将产生一个成功的口腔给药平台，可以减少毒性，提高疗效，并显著改善患者的依从性和生活质量。该项目的更广泛的影响/商业潜力将是一种口服不同药物的新技术，如化疗药物、抗生素或疫苗，该项目最初将专注于口腔癌，因为这一适应症、治疗和发展路径将提供最快和最大的许可和商业化机会。然后，该技术可以进行定制，以满足其他市场的特定需求。通过修改NP？S的属性和有效载荷，该平台可以针对各种产品、各种疾病和用途进行优化。

This Small Business Innovation Research (SBIR) Phase I project seeks to develop a novel drug delivery platform using an effective nano-encapsulation method capable of delivering a variety of drugs locally and systemically through buccal mucosa. The drug-loaded nanoparticles (NPs) are protected and housed in a bio-matrix sponge, which can also hold permeation enhancers and specific targeting motifs. A combination of these components will result in a successful buccal delivery platform that can reduce toxicity, increase efficacy and significantly improve patient compliance and quality of life.The broader impact/commercial potential of this project wil be a new technology for oral administration of different drugs, such as chemotherapeutics, antibiotics or vaccines, The projects will focus initially is oral cancer because this indication, treatment and developmental path will offer the fastest and greatest chance of licensing and commercialization. The technology can then be customized to meet the specific needs of other markets. By modifying NP?s properties and payloads, the platform can be optimized for variety of products, various diseases and purposes.